Biotechnology and Pharmaceutical Services Outsourcing Companies, Investment and Capital Allocation

Latest Updates of Key Players in the Biotechnology and Pharmaceutical Services Outsourcing Market

Parexel International Corporation

Headquarters: United States
Latest Update: This organization provides services for managing the biopharmaceutical product lifecycle and the development and commercialization of novel healthcare therapies.

The Quantic Group

Headquarters: New Jersey
Latest Update: The Quantic Group is a leading worldwide consultancy specializing in the pharmaceutical, biotechnology, and medical device fields.

Boston Scientific Corporation

Headquarters: United States
Latest Update: The Quantic Group is a pharmaceutical, biotechnology, vaccine, and medical device specialty consulting firm that supports both the industry and governments.

IQVIA

Headquarters: Germany
Latest Update: In June 2025, IQVIA, a leading global provider of clinical research solutions, commercial insights, and medical care intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris.

Lachman Consultant Services, Inc.

Headquarters: United State
Latest Update: Lachman Consultant Services, Inc. offers specialized biotech and pharma outsourcing via expert government, compliance, and scientific guidance.

GMP Pharmaceuticals Pty Ltd.

Headquarters: Australia
Latest Update: GMP Pharmaceuticals Pty Ltd is a leading Australasian contract manufacturer of complementary medicines, natural health products, and infant formulas.

Market Growth

The global biotechnology and pharmaceutical services outsourcing market size was estimated at USD 51.59 billion in 2025 and is predicted to increase from USD 54.54 billion in 2026 to approximately USD 89.82 billion by 2035, expanding at a CAGR of 5.7% from 2026 to 2035.

Recent Developments in the Market

• In January 2026, Zydus Lifesciences Limited, an innovation-led life-sciences company with an international presence, announced the successful closure of the Asset Purchase Agreement, Share Purchase Agreement, and the exclusive Licensing Agreement with Agenus Inc.
• In January 2026, ESTEVE and TerSera Therapeutics LLC announced that they had entered into an agreement in which ESTEVE will acquire TerSera's Infusion Specialty Therapies Business Unit (IST).  This strategic acquisition allows ESTEVE to expand its U.S. presence, with two highly specialized on-market assets and a dedicated team of sales, marketing, and healthcare professionals
• In October 2025, INTERPHEX, the leading global event for pharmaceutical and biotechnology innovation in the entire product advancement lifecycle, announced the launch of the Contract & Outsourcing Exchange (COEX), a devoted destination at INTERPHEX 2026 designed to unite the outsourcing community under one roof and offer a partnering platform for effective.
• In March 2025, AstraZeneca had an agreement in place to acquire Belgium-based EsoBiotec, a biotechnology company specializing in in-vivo cell therapies. EsoBiotec’s operations will continue in Belgium, with the company becoming a wholly owned subsidiary of AstraZeneca.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com